Global Antibiotics Market

Antibiotics Market Size, Share, Growth Analysis, By Drug class(Cephalosporin, Penicillin), By Action Mechanism(Cell Wall Synthesis, Protein Synthesis) - Industry Forecast 2024-2031

Report ID: SQMIG35B2164 | Region: Global | Published Date: April, 2024
Pages: 165 | Tables: 72 | Figures: 75

Antibiotics Market News

  • In February, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK's cephalosporin antibiotics business, reinforcing its leading global position in antibiotics. The agreement includes the global rights to three established brands i.e. Zinnat, Zinacef and Fortum in over 100 markets.
  • In January 2020, Merck & Co., Inc. announced the U.S. FDA approval for its DIFICID (fidaxomicin) for oral suspension and a supplemental New Drug Application (sNDA) for DIFICID tablets for the treatment of Clostridioides (formerly Clostridium) difficile-associated diarrhea (CDAD) in children aged six months and older.
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.



Antibiotics Market size was valued at USD 40.39 billion in 2019 and is poised to grow from USD 41.4 billion in 2023 to USD 50.3 billion by 2031, growing at a CAGR of 2.5% in the forecast period (2024-2031).

The Antibiotics Market is highly competitive, with the existence of huge number of major firms operating in both domestic and international markets. The industry's top players are embracing strategic collaboration initiatives to improve market share and profitability. Some of the major players in the market are Pfizer Inc., Merck & Co., Inc., Melinta Therapeutics, Allergan plc, Tetraphase Pharmaceuticals Basilea Pharmaceutica Ltd., among several others who are driving the market. 'Merck & Co., Inc.', 'Allergan plc (AbbVie)', 'GlaxoSmithKline plc.', 'Pfizer Inc.', 'Novartis AG', 'Sanofi S.A.', 'AstraZeneca plc', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V.', 'Eli Lilly and Company', 'Bayer AG', 'Bristol-Myers Squibb Company', 'AbbVie Inc.', 'Astellas Pharma Inc.', 'Boehringer Ingelheim GmbH', 'Daiichi Sankyo Company, Limited', 'Roche Holding AG', 'Sun Pharmaceutical Industries Ltd.', 'Takeda Pharmaceutical Company Limited.'

The expanded endeavors of drug organizations in the improvement of novel treatments to treat irresistible sicknesses are supposed to drive the market over the estimate period. Steady government regulation, for example, the Increase Act and Redo Act is expected to assist the endorsement cycle internationally. The send off of new antibiotic drugs is supposed to help the development of the market over the conjecture period.

As per the CDC, the frequency of antibiotic-safe contaminations is more than 2.8 million in the U.S. The microorganisms like Enterobacteriaceae, P. aeruginosa, and K. pneumoniae have a high resisting pace of around 40% in emerging nations.

Asia Pacific held the foremost market share in 2021 and is estimated to enlist a critical development rate over the forecast period. This can be credited to the maximum usage of antibiotics, expansion in the pervasiveness of irresistible sicknesses, and rising government drives to foster novel treatments to treat drug-safe diseases. Also, the presence of conventional players is adding to the development of the territorial market. India and China are the greatest business sectors for antibiotics in the district. Unregulated deals and exorbitant utilization of antibiotics are the key elements supporting the market development in these countries.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.


Feedback From Our Clients

Global Antibiotics Market

Product ID: SQMIG35B2164